Benzenetriols and derivatives
eMolecules 3,4,5-Trihydroxybenzamide | 618-73-5 | MFCD00014800 | 25g
Combi-Blocks, Inc. | 3,4,5-Trihydroxybenzamide | 25g | 569295508 | QF-3553 | 95.000 | 618-73-5 | MFCD00014800 | 169.136 | C7H7NO4
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool
Medchemexpress LLC AT-533 | 908112-37-8 | 98.4% | 410.51 | 100 MG
AT-533 is a potent Hsp90 and HSV inhibitor. It suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway and inhibits the activation of downstream pathways such as Akt/mTOR/p70S6K, Erk1/2, and FAK. Additionally, it inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs).
- Potent Hsp90 and HSV inhibitor
- Suppresses tumor growth
- Inhibits angiogenesis by blocking HIF-1α/VEGF/VEGFR-2 signaling
- Inhibits Akt/mTOR/p70S6K, Erk1/2, and FAK pathways
- Inhibits tube formation, cell migration, and invasion of HUVECs
- Shows anti-angiogenic ability in CAM model
- Decreases TNF-α, IL-1β, and IL-6 production
- No significant toxicity in animal studies
Medchemexpress LLC AT-533 | 908112-37-8 | 98.4% | 410.51 | 50 MG
AT-533 is a potent inhibitor of Heat Shock Protein 90 (Hsp90) and Herpes Simplex Virus (HSV). It demonstrates anti-tumor and anti-angiogenic properties by targeting the HIF-1α/VEGF/VEGFR-2 signaling pathway, and suppresses downstream pathways including Akt/mTOR/p70S6K, Erk1/2, and FAK.
- Potent Hsp90 and HSV inhibitor.
- Suppresses tumor growth and angiogenesis.
- Inhibits key signaling pathways: Akt/mTOR/p70S6K, Erk1/2, and FAK.
- Reduces tube formation, cell migration, and invasion in HUVECs.
- Demonstrates anti-angiogenic activity in CAM models.
- Decreases inflammatory markers TNF-α, IL-1β, and IL-6.
- Shows no adverse reactions in subacute toxicology studies.
eMolecules 6-HYDROXYDOPAMINE HYDROBROMIDE | 636-00-0 | 1G | Purity: 95%
AstaTech | 6-HYDROXYDOPAMINE HYDROBROMIDE | 1G | 636-00-0 | MFCD00012894
If you are unable to find the chemical you are looking for, make sure you are logged into your fishersci.com account and click on the following link:
eMolecules Building Block Tool
Sigma Aldrich Fine Chemicals Biosciences 6-Hydroxydopamine hydrobromide 95% | 636-00-0 | MFCD00012894 | 5G
6-Hydroxydopamine hydrobromide 95% | Purity: 95% | Mol Wt: 250.09 | 636-00-0 | MFCD00012894 | 5G
Sigma Aldrich Fine Chemicals Biosciences 6-Hydroxydopamine hydrobromide 95% | 636-00-0 | MFCD00012894 | 250MG
6-Hydroxydopamine hydrobromide 95% | Purity: 95% | Mol Wt: 250.09 | 636-00-0 | MFCD00012894 | 250MG
Medchemexpress LLC AT-533 | 908112-37-8 | 98.38% | 410.51 | 5 MG
AT-533 is a potent Hsp90 and HSV inhibitor. It suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. Additionally, AT-533 inhibits the activation of downstream pathways such as Akt/mTOR/p70S6K, Erk1/2, and FAK.
- Inhibits tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs).
- Decreases TNF-α, IL-1β, and IL-6 production in RAW264.7 and BV2 cells induced by HSV-1.
- Shows anti-angiogenic ability in a chorioallantoic membrane (CAM) model.
- Suppresses the expression of HIF-1α/VEGF signaling pathway-related proteins in MDA-MB-231 breast cancer xenografts in mice.
- Subacute toxicity tests showed no mortality, loss of appetite, body weight changes, or adverse reactions in Sprague-Dawley rats.
eMolecules Ambeed / 456-Trihydroxybenzene-13-dicarbaldehyde / 50mg / 665578396 / A1082348 / / 58343-12-7 / MFCD24676794 / 182.131 / C8H6O5
Ambeed / 456-Trihydroxybenzene-13-dicarbaldehyde / 50mg / 665578396 / A1082348 / / 58343-12-7 / MFCD24676794 / 182.131 / C8H6O5
Medchemexpress LLC AT-533 | 908112-37-8 | 98.4% | 410.51 | 1 ML
AT-533 is a potent inhibitor of Hsp90 and HSV, suppressing tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. It also inhibits the activation of downstream pathways like Akt/mTOR/p70S6K, Erk1/2, and FAK, and hinders tube formation, cell migration, and invasion in human umbilical vein endothelial cells (HUVECs).
- Potent Hsp90 and HSV inhibitor
- Suppresses tumor growth and angiogenesis
- Blocks HIF-1α/VEGF/VEGFR-2 signaling pathway
- Inhibits Akt/mTOR/p70S6K, Erk1/2, and FAK pathways
- Inhibits tube formation, cell migration, and invasion in HUVECs
- Decreases inflammatory cytokine production in HSV-1 induced cells
- Shows anti-angiogenic ability
Medchemexpress LLC AT-533 | 908112-37-8 | 98.4% | 410.51 | 25 MG
AT-533 is a potent inhibitor of Hsp90 and HSV. It inhibits tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. Additionally, AT-533 suppresses the activation of downstream pathways such as Akt/mTOR/p70S6K, Erk1/2, and FAK. It also inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs).
- Potent Hsp90 and HSV inhibitor.
- Suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway.
- Inhibits the activation of downstream pathways, including Akt/mTOR/p70S6K, Erk1/2, and FAK.
- Inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs).
Medchemexpress LLC Benzoic acid, 4-[4-[(2-bromoacetyl)amino]butyl]- | 10161-87-2 | 98.7% | 314.18 | 25 MG
KRA-533 is a potent KRAS agonist that binds to the GTP/GDP binding pocket in the KRAS protein to prevent GTP cleavage. This results in the accumulation of constitutively active GTP-bound KRAS, triggering apoptotic and autophagic cell death pathways in cancer cells.
- Enhances KRAS activity in HCC827 and H157 cells.
- Mediates cell growth suppression in H292 cells without KRAS mutation.
- Directly binds to WT, G12C, G12D, and G13D mutant KRAS proteins.
- Suppresses tumor growth and induces apoptosis and autophagy in mutant KRAS xenografts in vivo.
Accela Chembio Inc 1 | 2 | 4-trihydroxybenzene | 100g | 533-73-3 | MFCD00002198 | 95+% | Shelf Life: 1260 Days | Light Sensitive/n2/+4
1 | 2 | 4-trihydroxybenzene | 100g | 533-73-3 | MFCD00002198 | 95+% | Shelf Life: 1260 Days | Light Sensitive/n2/+4
Carbosynth LLC. 3,4,5-Trihydroxybenzamide | 618-73-5 | MFCD00014800 | 100g
This item has a minimum order quantity of 2 per supplier requirements
3,4,5-Trihydroxybenzamide | MW: 169.13 | 618-73-5 | MFCD00014800 | 100g
Medchemexpress LLC Benzoic acid, 4-[4-[(2-bromoacetyl)amino]butyl]- | 10161-87-2 | 98.7% | 314.18 | 10 MM * 1 ML
KRA-533 is a potent KRAS agonist that functions by binding to the GTP/GDP binding pocket in the KRAS protein, which prevents GTP cleavage. This action leads to the accumulation of constitutively active GTP-bound KRAS, subsequently triggering both apoptotic and autophagic cell death pathways in cancer cells.
- Potent KRAS agonist
- Binds to GTP/GDP binding pocket in KRAS protein
- Prevents GTP cleavage
- Triggers apoptotic and autophagic cell death pathways in cancer cells
- Enhances KRAS activity
- Suppresses tumor growth in lung cancer mutant KRAS xenografts
- Induces apoptosis and autophagy in tumor tissues
- Directly binds to WT, G12C, G12D, and G13D mutant KRAS proteins